Knight Therapeutics (TSX:GUD) reported quarterly earnings of $0.13 per share which beat the analyst consensus estimate of $0.01 by 1200 percent. This is a 550 percent increase over earnings of $0.02 per share from the same period last year. The company reported quarterly sales of $148.439 million which beat the analyst consensus estimate of $113.698 million by 30.55 percent. This is a 68.54 percent increase over sales of $88.076 million the same period last year.